Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 118

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 118
---
.                                                 |     | 2. Upon filing of the lesion,                                                                   
 UV beam cures GelrinC into a soft rubbery implant.                                              |
| 3. As GelrinC implant recedes                                                                                                            
 and resorbs, the cartilage lesion rim creates aggregates and new cartilage tissue filling up the void created by the retreating implant. |     | 4. At the end of 6-9 months                                                                     
 with functioning knee, GelrinC implant is resorbed and new cartilage covers the treated lesion. |

<div align='center'>71</div>

As demonstrated in the Pilot
Study, the advantages of GelrinC include:

| ● | An off-the-shelf product 
 for cartilage repair;    |

| ● | A new class of a-cellular 
 product solution;         |

| ● | Polyethylene glycol, or                                                                                                             
 PEG, implant preventing cellular migration as a primary mode of action and further aided by denatured fibrinogen controlled erosion 
 for the regeneration of hyaline-like cartilage;                                                                                     |

| ● | Initial state as liquid                                                                                                          
 form provides for complete and optimal defect filling and subsequent curing hardens it into a more solid body, and holding it in 
 place;                                                                                                                           |

| ● | Single, 10 minutes surgical 
 procedure;                  |

| ● | Implantable via open or                 
 minimally-invasive surgical techniques; |

| ● | Manufacturing process allows               
 for low cost of goods and scalability; and |

| ● | Intended for the repair                                     
 of focal defects in cartilage and/or osteochondral defects. |

All of these advantages were
demonstrated in the Pilot Study where the recovery of the patient took approximately two weeks of non-weight bearing activity, and led
to a full recovery within three to six months. Additionally, 100% of the participants who were followed up with in the Pilot study reported
no pain in their recovery through at least four years thereafter.

Future Products; Additional Applications

Based on similarity of mechanism
of action for cartilage and based on animal studies performed by the Company for osteoarthritis, we believe that in the future, our Gelrin
technology platform may also provide a solution to osteoarthritis and other cartilage injuries related to the ankle, wrist, and elbow.

| ● | GelrinP – a paste                                                                                                                      
 form of GelrinC, which is cured with UV light, developed for treatment of injuries in smaller joints